Evidence map›Paper›PMID 41208345›Full record

ReviewAddiction (Abingdon, England)2026

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups.

John Holmes, Christopher K Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E D Allison

Abstract readReview
In one paragraph

Review in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John HolmesSchool of Medicine and Population Health, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0001-9283-2151
Christopher K OldroydNational Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.ORCID https://orcid.org/0000-0002-4934-8345
Colin DrummondNational Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Matt FieldSchool of Psychology, University of Sheffield, Interdisciplinary Centre of the Social Sciences (ICOSS) Building, Sheffield, UK.ORCID https://orcid.org/0000-0002-7790-5559
Inge KersbergenSchool of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Michael E D AllisonNational Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.

Funding

National Institute for Health and Care Research NIHR302571National Institute for Health Research Applied Research Collaboration South LondonNIHR Maudsley Biomedical Research CentrePublic Health Research Programme NIHR135310
6 · The paper itself

Abstract

Alcohol-free and low-alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high-income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol-related health problems should take a zero-tolerance approach to these alcohol-like products or encourage patients to try them. We argue that no/lo drinks may have an important role to play for people who drink at high-risk levels and those with alcohol use disorders (AUD) or alcohol-related liver disease (ARLD), particularly where debate and guidance related to treatment of these problems considers goals other than abstinence. The limited available evidence available suggests no/lo drinks may be useful in supporting attempts to reduce alcohol consumption or maintain abstinence among high-risk drinkers who do not have severe AUD or ARLD; however, they may also entail significant risks of relapse in those recovering from AUD. We therefore need further experimental and longitudinal studies testing whether use of no/lo drinks can lead to, or support, reductions in alcohol consumption. We particularly need high-quality experimental studies to test whether exposure to and sustained use of no/lo drinks affects treatment and recovery outcomes. Evidence is also needed on which subgroups of AUD and ARLD patients would benefit or be at risk from use of either alcohol-free or low-alcohol drinks. Finally, guidance should recognise that many patients already use these products and that a zero-tolerance approach may alienate patients or erode trust in clinicians.

Indexed as

Alcohol DrinkingAlcoholic BeveragesAlcoholismAlcohol-Related DisordersAlcohol AbstinenceHumansalcohol dependencealcohol policyclinical guidelinesharmful drinkinghazardous drinkingliver cirrhosisnon‐alcoholictreatment guidelineszero alcohol

Identifiers

PMID41208345
PMCPMC13088919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.